Research Analysts Issue Forecasts for Alumis FY2029 Earnings

Alumis Inc. (NASDAQ:ALMS) – Research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Alumis in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($1.61) for the year. The consensus estimate for Alumis’ current full-year earnings is ($8.45) per share.

ALMS has been the subject of several other research reports. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Alumis in a research report on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Robert W. Baird assumed coverage on shares of Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price for the company. Finally, Oppenheimer initiated coverage on Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $27.57.

Alumis Stock Performance

Shares of NASDAQ:ALMS opened at $6.59 on Thursday. Alumis has a 52-week low of $6.29 and a 52-week high of $13.53. The stock’s fifty day simple moving average is $7.93 and its 200-day simple moving average is $10.30.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in Alumis during the second quarter worth about $3,376,000. Towerview LLC grew its holdings in shares of Alumis by 22.6% during the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after purchasing an additional 70,000 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in Alumis during the 3rd quarter worth approximately $1,160,000. BNP Paribas Financial Markets purchased a new position in Alumis in the third quarter valued at approximately $27,000. Finally, MetLife Investment Management LLC acquired a new position in Alumis during the third quarter valued at approximately $89,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.